Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus ZYRTEC.
FEXOFENADINE HYDROCHLORIDE HIVES vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
60 mg orally twice daily or 180 mg orally once daily
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%).
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category A/B
Category C
Antihistamine
Antihistamine